Is LiveRamp Holdings (RAMP) the Best Affordable Tech Stock to Buy According to Analysts?
Stock affordability can be assessed in multiple ways. The most common approach is considering stocks with a market price below a certain threshold. Another method is evaluating stocks based on relative valuation metrics, such as a low price-to-earnings (P/E) ratio or other similar multiples. While we have earlier written about undervalued stocks based on P/Es (Read: ), the focus for this article is a blend of both the approaches. Apart from low valuation, investors are often drawn to lower-priced stocks, particularly those under $50, because even small price movements can lead to significant percentage gains. Additionally, many investors prefer owning a larger number of shares in lower-priced stocks rather than a few shares in higher-priced ones.
However, a stock's affordability alone does not determine its quality or long-term potential. Key factors such as financial stability, business execution, and overall market conditions play a crucial role in a stock's performance.
Affordable tech stocks are often found in the small- and mid-cap space, particularly within the $10-$50 range, which is the focus of this article. Recently, interest in small- and mid-cap stocks has increased following the volatility in the Magnificent 7 (Mag 7) mega-cap tech stocks. Chris Retzler, portfolio manager of the Needham Small Cap Growth Fund, discussed the outlook for small-cap stocks on CNBC's Squawk Box on January 17. He noted that while small-cap stocks have underperformed broader market indexes, recent momentum in the Russell 2000 suggests a potential shift. Chris emphasized that small-cap companies are seeking greater economic stability, which, once established, could drive broader market participation and growth. He also highlighted ongoing innovation in industries such as electric vehicles, semiconductors, and data infrastructure, which could benefit smaller firms.
Similarly, in mid-February, Gene Munster, managing partner at Deepwater Asset Management, discussed a potential shift from mega-cap tech stocks toward smaller technology companies. While he remains optimistic about the long-term prospects of the Mag 7, he believes that smaller tech firms—particularly those with a market cap below $500 billion could start outperforming as investors look for new growth opportunities.
Identifying the best affordable tech stocks is particularly challenging, given the sector's dynamic nature and recent volatility. To gain further insights, we look at another discussion on CNBC from March 24, where Gene Munster again shared his outlook on the tech sector. He pointed to April 2 as a key event, as new tariffs are set to take effect. While acknowledging short-term volatility, Munster remains bullish on tech stocks for the next two years, viewing the market as still in the early stages of an AI-driven growth cycle, unless disrupted by a potential recession.
Despite short-term fluctuations and external factors like tariffs, the long-term outlook for tech remains strong, especially for companies positioned to capitalize on AI-driven growth and broader industry trends. That said, given the recent volatility in large tech stocks, opportunities in small- and mid-cap tech companies have come to the fore, particularly for those with strong financials and innovative offerings. As investors look beyond the Magnificent 7 and large cap tech companies, affordable tech stocks in sectors like AI, semiconductors, and data infrastructure could benefit from increased market attention.
To identify the best affordable tech stocks to buy according to analysts, we screened for U.S.-listed companies with a share price between $10 and $50 and a market capitalization above $1 billion. These criteria helped us avoid volatile small-cap stocks. Next, we narrowed the selection to stocks trading at or below a forward price-to-earnings (P/E) ratio of 20 while also having an upside potential of at least 20%. From this refined list, we further filtered companies that are widely held by hedge funds, using data from Insider Monkey's Q4 2024 hedge fund holdings database. Finally, we ranked the top 12 stocks based on their upside potential, placing those with the highest projected gains at the top.Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
A close-up view of a modern server rack, with its bright blinking lights.LiveRamp Holdings Inc. (NYSE:RAMP) provides a data collaboration platform that enables businesses to securely utilize data for marketing and customer insights. Its technology facilitates first-party data sharing between trusted partners while ensuring privacy compliance. The company serves clients worldwide.
LiveRamp Holdings Inc. (NYSE:RAMP) is experiencing strong growth, with a total addressable market (TAM) of $13 billion, over 60% of which is driven by its Data Room and Audience Addressability offerings. As the company plans to expand into new industries, TAM is projected to increase to $35 billion. LiveRamp aims to sustain profitable growth, targeting the 'Rule of 40' by FY 2028, with 10-15% revenue growth and a 25-30% non-GAAP operating margin. Rule of 40 is a key metric in software where revenue growth and profit margin should combine to reach at least 40, indicating efficiency of the business.
Recent financial results highlight this momentum. In Q3 2025 (fiscal year ending March), revenue rose 12% year-over-year to $195 million, exceeding guidance by $4 million. Subscription revenue grew 10% to $146 million, while improved margins drove EPS up 17% to $0.55. Encouraged by these results, LiveRamp (NYSE:RAMP) raised its full-year revenue guidance, now expecting $741-$743 million for FY 2025.
Analysts recognize the company's steady growth. On February 27, Evercore ISI analyst Kirk Materne reaffirmed a Buy rating, setting a $45 price target, implying a 62% upside potential.
Overall, RAMP ranks 2nd on our list of best affordable tech stocks to buy according to analysts. While we acknowledge the potential of RAMP to grow, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than RAMP but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: and .
Disclosure: None. This article is originally published at .
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
Options Traders Brace for Big Tech Selloff With ‘Disaster' Puts
(Bloomberg) -- Options traders are increasingly nervous about a plunge in technology stocks in the coming weeks and are grabbing insurance to protect themselves from a wipeout. The tech-heavy Nasdaq 100 Index is up almost 40% since its early April plunge triggered by President Donald Trump's sweeping tariffs. The rally has been propelled by big tech, with the Bloomberg Magnificent 7 Index — which contains the likes of Nvidia Corp., Meta Platforms Inc. and Microsoft Corp. — soaring nearly 50% since its April 8 bottom. Chicago Schools Seeks $1 Billion of Short-Term Debt as Cash Gone A Photographer's Pipe Dream: Capturing New York's Vast Water System A London Apartment Tower With Echoes of Victorian Rail and Ancient Rome Why New York City Has a Fleet of New EVs From a Dead Carmaker Princeton Plans New Budget Cuts as Pressure From Trump Builds The concern, however, is that those gains are hiding areas of weakness lurking beneath the market's surface. And there are potential triggers for a drop coming up, from Federal Reserve's Jackson Hole symposium starting in a few days to Nvidia's earnings next week. Traders are 'less concerned' about a 'normal run-of-the-mill pullback' and seem to be more worried about a repeat of the April selloff, said Jeff Jacobson, head of derivative strategy at 22V Research Group, who thinks a shallower dip is more likely. Traders are buying 'disaster' puts on the Invesco QQQ Trust Series 1 ETF, which tracks the Nasdaq 100 Index, Jacobson said. Put options give investors the right to sell the underlying security at a certain price, and are popular as a way of protecting against a market drop. A measure showing the difference between the cost of hedging against a sharp downturn and a smaller one is at an almost three-year high, Jacobson said. Fears of a bubble are mounting, as tech stocks follow a pattern that is 'surprisingly similar' to the dot-com bubble of the late 1990s, Torsten Slok, chief economist at Apollo Management, wrote in a note to clients on Monday. Meanwhile, Michael Hartnett, chief investment strategist at Bank of America Corp., has been warning of a bubble forming in risk assets since December and predicts that US stocks will drop after the Fed's Jackson Hole symposium ends on Friday. Myriad Risks 'The market's had such a big run,' Jacobson said. 'A myriad of things' could send big tech tumbling. For example, there are worries about the impact of artificial intelligence on software companies, which has helped push Salesforce Inc.'s share price down 27% this year. And the Magnificent 7 rally could come to an end if tariff-driven inflation forces the Fed to curtail interest rate cuts that the market has already priced in. 'It could be a rotation out of those the Mag Seven names into some of the other areas that have lagged,' Jacobson said. 'It could be 'sell the news' when you have Nvidia earnings in the next few weeks. We could even get a 'sell the news' out of Jackson Hole.' The elevated put skew indicates that traders are hedging against a repeat of the tariff tantrum in April, according to Jacobson. He sees that fear as overblown. While the Nasdaq 100 sank more than 20% from its Feb. 9 high to its April 8 low, that kind of move is extremely unusual. Over the last 18 months, the average selloff in the Nasdaq 100 has been around 12.5%, Jacobson said. To bet on a correction in the ETF, Jacobson suggests a number of trades including buying a put ratio spread, in which cost of insuring against a shallower drop is partially funded by selling insurance against a deeper, April-style plunge. Specifically, Jacobson encourages traders to buy $570 puts in QQQ that expire on Oct. 17, and that they fund the trade by selling twice as many $515 puts in QQQ. The trade should make money if the index falls by roughly 2% and no more than 11%, he said. The $515 level is the ETF's 200-day moving average, which he believes will act as a floor in the event of a pullback. Not everyone on Wall Street is convinced that investors should be shorting the best performing of the major US equity indexes over the last decade. JPMorgan Chase & Co. cross-asset strategists, for instance, suggest shorting the small-capitalization Russell 2000 Index and going long the Nasdaq 100. Jacobson, however, is more pessimistic about big tech's immediate future. 'Clearly, there's a possibility, right?' he asked rhetorically. 'You have just a, such a strong concentration in these names. It wouldn't take much.' Foreigners Are Buying US Homes Again While Americans Get Sidelined What Declining Cardboard Box Sales Tell Us About the US Economy Women's Earnings Never Really Recover After They Have Children Americans Are Getting Priced Out of Homeownership at Record Rates Yosemite Employee Fired After Flying Trans Pride Flag ©2025 Bloomberg L.P.
Yahoo
35 minutes ago
- Yahoo
Viking Therapeutics stock falls 37% on high dropout rate in obesity trial
-- Viking Therapeutics (NASDAQ:VKTX) stock plunged as much as 37% Tuesday after revealing results from its Phase 2 VENTURE-Oral Dosing trial for its oral obesity treatment, while Eli Lilly (NYSE:LLY) shares gained 1.5% as analysts pointed to competitive advantages. The trial demonstrated that Viking's oral tablet formulation of VK2735, a dual GLP-1 and GIP receptor agonist, met its primary endpoint with patients losing up to 12.2% of body weight after 13 weeks compared to 1.3% for placebo. Despite the weight loss efficacy, the 28% treatment discontinuation rate among patients receiving VK2735 versus 18% for placebo raised significant concerns among investors and analysts. Mizuho analyst Jared Holz highlighted competitive disadvantages compared to Eli Lilly's offerings: "Data look inferior to LLY on almost all metrics and the thing to consider here is that patients discontinued at such a high rate over 13-weeks vs. LLY in the mid 20% range --- but over 72-weeks; A much longer trial, and therefor LLY looks far better head-to-head. This probably shutters hope for VKTX a bigtime player in the oral obesity market over the near to medium term." JPMorgan (NYSE:JPM) analyst Hardik Parikh offered a more balanced view, noting, "In 13 weeks, the three highest-dosing arms of 60/90/120mg showed avg pbo-adj weight loss of ~7.5%, 10%, 11%, which we think is very strong compared with other orals in development. Tolerability overall was manageable, but it was worse than we expected based on the ph1 performance." Parikh added that while the adverse event profile wasn't as clean as in Phase 1 trials, "we still think oral vk-2735 offers strong efficacy with a manageable tolerability profile." Viking reported that 99% of gastrointestinal-related adverse events were mild or moderate. The company also highlighted an exploratory maintenance dosing arm showing weight loss could be maintained at lower doses. The major adverse events included vomiting rates of 20-35% in the three highest dose arms compared to about 10% for placebo, and nausea rates of approximately 58% for patients on treatment versus 48% for placebo. Related articles Viking Therapeutics stock falls 37% on high dropout rate in obesity trial Tesla robotaxi trial impresses, pricing power clear: William Blair Palo Alto Networks gains after strong earnings and Bank of America upgrade
Yahoo
36 minutes ago
- Yahoo
Is Most-Watched Stock JD.com, Inc. (JD) Worth Betting on Now?
Inc. (JD) is one of the stocks most watched by visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over the past month, shares of this company have returned -4.9%, compared to the Zacks S&P 500 composite's +2.5% change. During this period, the Zacks Internet - Commerce industry, which falls in, has gained 2.3%. The key question now is: What could be the stock's future direction? Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision. Revisions to Earnings Estimates Here at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock. Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. is expected to post earnings of $0.40 per share for the current quarter, representing a year-over-year change of -67.7%. Over the last 30 days, the Zacks Consensus Estimate remained unchanged. For the current fiscal year, the consensus earnings estimate of $2.49 points to a change of -41.6% from the prior year. Over the last 30 days, this estimate has changed +0.3%. For the next fiscal year, the consensus earnings estimate of $3.61 indicates a change of +45.2% from what is expected to report a year ago. Over the past month, the estimate has changed +0.3%. With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #5 (Strong Sell) for The chart below shows the evolution of the company's forward 12-month consensus EPS estimate: 12 Month EPS Revenue Growth Forecast Even though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial. In the case of the consensus sales estimate of $40.08 billion for the current quarter points to a year-over-year change of +8%. The $183.33 billion and $192.78 billion estimates for the current and next fiscal years indicate changes of +14% and +5.2%, respectively. Last Reported Results and Surprise History reported revenues of $49.79 billion in the last reported quarter, representing a year-over-year change of +24.2%. EPS of $0.69 for the same period compares with $1.29 a year ago. Compared to the Zacks Consensus Estimate of $46.93 billion, the reported revenues represent a surprise of +6.1%. The EPS surprise was +38%. The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period. Valuation No investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance. While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price. The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued. is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade. Conclusion The facts discussed here and much other information on might help determine whether or not it's worthwhile paying attention to the market buzz about However, its Zacks Rank #5 does suggest that it may underperform the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Inc. (JD) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
